Effects of dihydroartemisinin combined with cisplatin on proliferation, apoptosis and migration of HepG2 cells

Rao,Qi; Li,Ruochan; Yu,He; Xiang,Lei; He,Bin; Wu,Fenghua; Zhao,Gang

doi:10.3892/ol.2022.13395

Effects of dihydroartemisinin combined with cisplatin on proliferation, apoptosis and migration of HepG2 cells

Authors:
- Qi Rao
- Ruochan Li
- He Yu
- Lei Xiang
- Bin He
- Fenghua Wu
- Gang Zhao
View Affiliations

Affiliations: Department of Medical Biology, School of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, P.R. China
Published online on: June 22, 2022 https://doi.org/10.3892/ol.2022.13395
Article Number: 275
Copyright: © Rao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin (DDP) is a potent and widely applied chemotherapeutic agent. However, its clinical efficacy for the treatment of liver cancer is limited by adverse effects and the development of resistance. Combinatorial therapy may alleviate these issues. Dihydroartemisinin (DHA) is a first‑generation derivative of artemisinin. The effects of DDP on liver cancer when applied in combination with DHA have not previously been studied. Therefore, the present study aimed to investigate the effects of DHA combined with DDP on HepG2 cells and their potential underlying molecular mechanisms. HepG2 cells were treated with different concentrations of DHA and/or DDP. Cell Counting Kit‑8 assay was used to assess the cell viability. Cell proliferation and apoptosis were quantified using flow cytometry, acridine orange/ethidium bromide (AO/EB) fluorescent dual staining and the colony formation assay. Cell migration was quantified using the Transwell and wound healing assays. The HepG2 cell protein expression levels of Fas, Fas‑associated death domain (FADD), procaspase‑3, cleaved caspase‑3, pro‑caspase‑8, cleaved caspase‑8, Bax, Bcl‑2, E‑cadherin and N‑cadherin, were detected via western blotting. Gelatin zymography was used to assess the levels of MMP‑9 secreted by HepG2 cells into the supernatant. Following combined DHA and DDP treatment, the percentage of apoptotic cells was significantly increased, whereas cell proliferation and migration were significantly reduced, compared with cells treated with DDP only. DHA and DPP in combination significantly inhibited the expression of MMP‑9, significantly increased the protein expression levels of Fas, FADD, Bax and E‑cadherin, significantly increased the ratio of cleaved caspase‑3 and cleaved caspase‑8 to their precursor proteins and significantly decreased the protein expression levels of Bcl‑2 and N‑cadherin. The findings of the present study suggested that, DHA may confer synergistic effects with DDP in potentially promoting apoptosis and inhibiting the epithelial‑mesenchymal transition for the treatment of liver cancer.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Wang Y, Liu Y, Liu Y, Zhou W, Wang H, Wan G, Sun D, Zhang N and Wang Y: A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma. Int J Pharm. 483:89–100. 2015. View Article : Google Scholar : PubMed/NCBI
3	El Dika I, Makki I and Abou-Alfa GK: Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin Oncol. 10:122021. View Article : Google Scholar : PubMed/NCBI
4	Anwanwan D, Singh SK, Singh S, Saikam V and Singh R: Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020. View Article : Google Scholar : PubMed/NCBI
5	Gurzu S, Kobori L, Fodor D and Jung I: Epithelial mesenchymal and endothelial mesenchymal transitions in hepatocellular carcinoma: A review. Biomed Res Int. 2019:29625802019. View Article : Google Scholar : PubMed/NCBI
6	Demir T, Lee SS and Kaseb AO: Systemic therapy of liver cancer. Adv Cancer Res. 149:257–294. 2021. View Article : Google Scholar : PubMed/NCBI
7	Dutta S, Mahalanobish S, Saha S, Ghosh S and Sil PC: Natural products: An upcoming therapeutic approach to cancer. Food Chem Toxicol. 128:240–255. 2019. View Article : Google Scholar : PubMed/NCBI
8	Ghosh S: Cisplatin: The first metal based anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
9	Fuertes MA, Alonso C and Pérez JM: Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem Rev. 103:645–662. 2003. View Article : Google Scholar : PubMed/NCBI
10	Oun R and Rowan E: Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node? Eur J Pharmacol. 811:125–128. 2017. View Article : Google Scholar : PubMed/NCBI
11	Pabla N and Dong Z: Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73:994–1007. 2008. View Article : Google Scholar : PubMed/NCBI
12	Santos NAGD, Ferreira RS and Santos ACD: Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food Chem Toxicol. 136:1110792020. View Article : Google Scholar : PubMed/NCBI
13	Astolfi L, Ghiselli S, Guaran V, Chicca M, Simoni E, Olivetto E, Lelli G and Martini A: Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation. Oncol Rep. 29:1285–1292. 2013. View Article : Google Scholar : PubMed/NCBI
14	Miller LH and Su X: Artemisinin: Discovery from the Chinese herbal garden. Cell. 146:855–858. 2011. View Article : Google Scholar : PubMed/NCBI
15	Ma N, Zhang Z, Liao F, Jiang T and Tu Y: The birth of artemisinin. Pharmacol Ther. 216:1076582020. View Article : Google Scholar : PubMed/NCBI
16	Haynes RK: From artemisinin to new artemisinin antimalarials: Biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. Curr Top Med Chem. 6:509–537. 2006. View Article : Google Scholar : PubMed/NCBI
17	Dai X, Zhang X, Chen W, Chen Y, Zhang Q, Mo S and Lu J: Dihydroartemisinin: A potential natural anticancer drug. Int J Biol Sci. 17:603–622. 2021. View Article : Google Scholar : PubMed/NCBI
18	Chen X, He LY, Lai S and He Y: Dihydroartemisinin inhibits the migration of esophageal cancer cells by inducing autophagy. Oncol Lett. 20:942020. View Article : Google Scholar : PubMed/NCBI
19	Wu L, Pang Y, Qin G, Xi G, Wu S, Wang X and Chen T: Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives. PLoS One. 12:e01718402017. View Article : Google Scholar : PubMed/NCBI
20	Zhang R, Niu Y and Zhou Y: Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol Lett. 192:108–114. 2010. View Article : Google Scholar : PubMed/NCBI
21	Raudenska M, Balvan J, Fojtu M, Gumulec J and Masarik M: Unexpected therapeutic effects of cisplatin. Metallomics. 11:1182–1199. 2019. View Article : Google Scholar : PubMed/NCBI
22	Kiss RC, Xia F and Acklin S: Targeting DNA damage response and repair to enhance therapeutic index in cisplatin-based cancer treatment. Int J Mol Sci. 22:81992021. View Article : Google Scholar : PubMed/NCBI
23	Sun Y, Jiang W, Lu W, Song M, Liu K, Chen P, Chang A, Ling J, Chiao PJ, Hu Y and Huang P: Identification of cisplatin sensitizers through high-throughput combinatorial screening. Int J Oncol. 53:1237–1246. 2018.PubMed/NCBI
24	Liu L, Fan J, Ai G, Liu J, Luo N, Li C and Cheng Z: Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells. Biol Res. 52:372019. View Article : Google Scholar : PubMed/NCBI
25	Rejhová A, Opattová A, Čumová A, Slíva D and Vodička P: Natural compounds and combination therapy in colorectal cancer treatment. Eur J Med Chem. 144:582–594. 2018. View Article : Google Scholar : PubMed/NCBI
26	Abe K, Yamamoto N, Hayashi K, Takeuchi A and Tsuchiya H: Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo. BMC Cancer. 19:6892019. View Article : Google Scholar : PubMed/NCBI
27	Tu Y: The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med. 17:1217–1220. 2011. View Article : Google Scholar : PubMed/NCBI
28	Angus B: Novel anti-malarial combinations and their toxicity. Expert Rev Clin Pharmacol. 7:299–316. 2014. View Article : Google Scholar : PubMed/NCBI
29	Wan X, Zhong H, Pan W, Li Y, Chen Y, Li N and Tang B: Programmed release of dihydroartemisinin for synergistic cancer therapy using a CaCO₃ mineralized metal-organic framework. Angew Chem Int Ed Engl. 58:14134–14139. 2019. View Article : Google Scholar : PubMed/NCBI
30	Im E, Yeo C, Lee HJ and Lee EO: Dihydroartemisinin induced caspase-dependent apoptosis through inhibiting the specificity protein 1 pathway in hepatocellular carcinoma SK-Hep-1 cells. Life Sci. 192:286–292. 2018. View Article : Google Scholar : PubMed/NCBI
31	Li Q, Ma Q, Cheng J, Zhou X, Pu W, Zhong X and Guo X: Dihydroartemisinin as a sensitizing agent in cancer therapies. Onco Targets Ther. 14:2563–2573. 2021. View Article : Google Scholar : PubMed/NCBI
32	Tai X, Cai XB, Zhang Z and Wei R: In vitro and in vivo inhibition of tumor cell viability by combined dihydroartemisinin and doxorubicin treatment, and the underlying mechanism. Oncol Lett. 12:3701–3706. 2016. View Article : Google Scholar : PubMed/NCBI
33	Jin H, Jiang AY, Wang H, Cao Y, Wu Y and Jiang XF: Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway. Mol Med Rep. 16:3475–3481. 2017. View Article : Google Scholar : PubMed/NCBI
34	Dasari S, Njiki S, Mbemi A, Yedjou CG and Tchounwou PB: Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy. Int J Mol Sci. 23:15322022. View Article : Google Scholar : PubMed/NCBI
35	Qi L, Luo Q, Zhang Y, Jia F, Zhao Y and Wang F: Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 32:1469–1486. 2019. View Article : Google Scholar : PubMed/NCBI
36	Makovec T: Cisplatin and beyond: Molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol. 53:148–158. 2019. View Article : Google Scholar : PubMed/NCBI
37	Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S and Yu L: The drug-resistance mechanisms of five platinum-based antitumor agents. Front Pharmacol. 11:3432020. View Article : Google Scholar : PubMed/NCBI
38	Mao H, Gu H, Qu X, Sun J, Song B, Gao W, Liu J and Shao Q: Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. Int J Mol Med. 31:213–218. 2013. View Article : Google Scholar : PubMed/NCBI
39	Hu YJ, Zhang JY, Luo Q, Xu JR, Yan Y, Mu LM, Bai J and Lu WL: Nanostructured dihydroartemisinin plus epirubicin liposomes enhance treatment efficacy of breast cancer by inducing autophagy and apoptosis. Nanomaterials (Basel). 8:8042018. View Article : Google Scholar : PubMed/NCBI
40	Wang Y, Liu Y, Xiang L, Han L, Yao X, Hu Y and Wu F: Cyclin D1b induces changes in the macrophage phenotype resulting in promotion of tumor metastasis. Exp Biol Med (Maywood). 246:2559–2569. 2021. View Article : Google Scholar : PubMed/NCBI
41	Bao Y, Zhang Y, Lu Y, Guo H, Dong Z, Chen Q, Zhang X, Shen W, Chen W and Wang X: Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition. Int J Biol Sci. 16:827–837. 2020. View Article : Google Scholar : PubMed/NCBI
42	Du B and Shim JS: Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 21:9652016. View Article : Google Scholar : PubMed/NCBI
43	Pastushenko I and Blanpain C: EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI